• Osteosarcoma, a type of bone cancer, affects ~ 800 humans per year and up to 45,000 dogs per year

  • This malignant bone tumor affects most commonly older large and giant breed dogs although a second peak incidence occurs in dogs 18-24 months of age

  • Poorly defined heritable risk factors are responsible for the well-recognized strong breed predispositions towards disease in large and giant breed dogs

  • Clinical signs, biological and genetic factors, therapeutic options and metastatic potential of osteosarcoma are comparable with the pediatric disease. 

  • Standard of care for dogs with osteosarcoma includes amputation of the affected limb and adjuvant platinum-based chemotherapy protocols

  • Most canine patients develop pulmonary metastases and succumb to their disease within 10-12 months of diagnosis

  • Novel treatments are needed to improve the survival of dogs with osteosarcoma and development of these treatments will increase our understanding of the disease and provide improved treatment options for dogs and children with osteosarcoma

Screen Shot 2019-03-28 at 1.12.18 PM.png

Evidence of T cell exclusion from a pulmonary metastatic lesion removed by minimally invasive surgery in a dog following treatment with immunotherapy